Intelligence Platform
Clinical trials, SEC filings,
hedge fund positioning,
and how they connect.
One database, organized by company, updated daily from primary sources. Built for BD, investors, and strategy teams.
$499/mo
Cancel anytime. Access continues through the end of the billing period.
Live Platform Data
On the platform right now, from primary sources.
Updated Sep 28, 2026
Endpoint modifications, enrollment shifts, and status changes detected automatically for every registered trial.
A new secondary endpoint, "Absolute Change from Baseline in 24-hour Cough Frequency", was added.
Completion date: 2026-09-30 → 2026-11-30
Trial stopped: Withdrawal of the marketing authorization for the breast cancer indication of Talzenna® in Korea, not related to safety...
Hedge fund ownership disclosures: who's building positions, reducing stakes, or going activist. Cross-referenced with trial events and 8-Ks.
Perceptive Advisors
BVF Partners L.P.
Stonepine Capital Management, LLC
8-K filings classified by type: licensing deals, FDA actions, financing events, and strategic reviews, identified automatically.
Tessera Defense and Homeland Security Inc., through its subsidiary Tessera Israel, entered into an Option Agreement with X S.E. Security and Defense Ltd. to potentially acquire a 51% stake in RT LTA Systems Ltd., a developer of tethered aerostat systems for surveillance. Tessera Israel paid $1 million for this 90-day option, which is creditable against the purchase price if exercised. The total purchase price for the 51% stake is capped at $13 million, with payments structured upon option exercise and based on RT's future financial performance.
Gossamer Bio, Inc. secured a private placement agreement to raise up to $250 million, with an initial $25.0 million closing. Additional funds of $125.0 million are contingent on FDA acceptance of the NDA for seralutinib in pulmonary arterial hypertension (PAH) by 2026, and a further $100.0 million from warrants upon FDA approval. Proceeds will support the clinical development and potential commercialization of seralutinib for PAH and PH-ILD.
Adagio Medical Holdings, Inc. has initiated a process to explore a full range of strategic alternatives to enhance shareholder value, which may include M&A. Concurrently, the company is reducing its workforce by 25 out of 43 full-time employees, effective September 23, 2026, anticipating approximately $1.3 million in cash expenditures for severance and related costs. The company also lowered the conversion price for its 13% Senior Secured Convertible Notes to facilitate potential conversions during this period.
All items link to original SEC documents and registry records on the platform.
Data
Primary sources, all linked.
Every data point traces to the original filing or registry record. No news, no analyst commentary, no third-party data vendors.
ClinicalTrials.gov
450K+ trials. Status, enrollment, endpoints, results, and change tracking. Updated daily.
SEC EDGAR
8-K, 10-K, 10-Q, Form 4, 13D/13G, 13F and more. Parsed and classified. Updated multiple times daily.
Financial Data
Filter companies by market cap, cash, expenses, and more for 500+ biotech companies.
FDA Data
Drug products, patent listings, and exclusivity records. Integrated
app.rxdatalab.com
What you can do
Built for BD, investors, and strategy teams who work from primary sources rather than news and analyst commentary.
Track a company across every source
Trial pipeline, 8-Ks, Regulatory filings, and financials in one view. Every item links to the original source document or registry record.
Monitor trial changes automatically
Daily comparison against ClinicalTrials.gov catches endpoint modifications, enrollment changes, arm updates, and status shifts. Nothing buried in the registry.
See who's building positions in biotech
Fund profiles with full position history and filing records. Multi-fund convergence on the same company. 13D/G cross-referenced with 8-K events and trial milestones.
See live data sample →Search SEC filings by what they mean
8-K filings classified into financing events, FDA actions, clinical results, licensing deals, and strategic reviews. Search by company, date range, or filing type, not just keyword.
See live data sample →Map competitive landscapes
Search by indication and surface every company running trials for that indication or related indications. Overlay financial position and recent trial events across the competitive field.
Organize research with projects and notes
Create projects with company and trial watchlists. Add timestamped notes directly on company and trial pages. Dashboard shows what changed across your coverage since your last session.
Data In Context
Every event, in context.
Financing events, licensing deals, trial changes, and hedge fund moves — overlaid on the quarterly financial timeline for Solid Biosciences Inc. (SLDB). Toggle layers, hover annotations, click any event to see the original source.
Competitive Landscape
Explore the competitive biotech landscape.
Search any indication. We map every industry trial using the NLM's MeSH medical ontology, then overlays institutional ownership, financial position, and recent trial events across the competitive field.
Condition Landscape
Active industry trials per condition. Search any condition on the platform.
Active Sponsors
| Company | Mkt Cap | Trials | Cash | Qtr Exp |
|---|---|---|---|---|
| Legend Biotech Corp LEGN | $3.7B | 1 | — | — |
| Cullinan Therapeutics, Inc. CGEM | $910M | 1 | $79M | $57M |
| Autolus Therapeutics plc AUTL | $494M | 1 | $171M | $69M |
| C4 Therapeutics, Inc. CCCC | $367M | 3 | $79M | $33M |
| Caribou Biosciences, Inc. CRBU | $133M | 2 | $26M | $27M |
| Karyopharm Therapeutics Inc. KPTI | $37M | 2 | $55M | $55M |
| Cellectar Biosciences, Inc. CLRB | $17M | 1 | $34M | $7M |
| Senti Biosciences, Inc. SNTI | $10M | 1 | $8M | $14M |
Sample data. Financial data from parsed 10-K/Q filings. Qtr Exp = R&D + G&A per quarter.
Trial monitoring
Trials can quietly change, don't miss it
Daily comparison against ClinicalTrials.gov. Every endpoint modification, enrollment shift, and status change categorized and summarized automatically.
NCT07525206
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
AbbVie Inc. ABBV
Enrollment
990
Primary Completion
2029-05
Detected
Sep 15, 2026
Secondary endpoint 1 timeframe
+ 1 more change detected
AI Summary
Two secondary endpoints related to EORCT QLQ-C30 domains were removed. Two new secondary endpoints were added, focusing on Overall Survival (OS) in participants with c-Met subgroups (< 10%, 3+ and >= 10%, 3+). The primary endpoints remain unchanged.
Full change history per trial. Every detection timestamped and linked to the original registry record.
Subscribe to access →Pricing
Simple, transparent pricing.
Individual — Monthly
Billed monthly. Cancel anytime from your account page.
- ✓ Full platform access
- ✓ BioHedge (13D/G fund positioning)
- ✓ Clinical trial change detection
- ✓ 8-K signal detection
- ✓ Competitive landscape mapping
- ✓ Research workspace and notes
Teams & Institutions
Custom pricing
For teams, firms, and institutional users who need multi-seat access, custom coverage, AI Access, API Access, or enterprise billing.
- ✓ Multi-seat access
- ✓ Custom data coverage and exports
- ✓ Invoiced billing and enterprise contracts
- ✓ API access and custom data feeds
- ✓ Dedicated support
What happens after payment?
You'll receive a welcome email with a link to set your password. Access immediately once your password is set.
How do I cancel?
Go to your account page and click "Manage Billing." Access continues through the end of your billing period.
Do you offer trials or demos?
The public pages at app.rxdatalab.com/biohedge and app.rxdatalab.com/strategic-signals show live data and require no login.
Questions or enterprise pricing?
Email [email protected] for team access, institutional pricing, or anything else.
By subscribing you agree to our Terms of Service and Data License Agreement.